Compare ARTNA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | OBIO |
|---|---|---|
| Founded | 1905 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 362.4M |
| IPO Year | 1996 | 2020 |
| Metric | ARTNA | OBIO |
|---|---|---|
| Price | $32.96 | $5.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.43 |
| AVG Volume (30 Days) | 24.8K | ★ 260.2K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | 11.62 | ★ 33.13 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $112,941,000.00 | $33,482,000.00 |
| Revenue This Year | $3.59 | N/A |
| Revenue Next Year | $4.27 | $33.03 |
| P/E Ratio | $27.67 | ★ N/A |
| Revenue Growth | 4.62 | ★ 1169.22 |
| 52 Week Low | $30.50 | $3.46 |
| 52 Week High | $36.98 | $6.50 |
| Indicator | ARTNA | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 48.61 |
| Support Level | $31.88 | $3.67 |
| Resistance Level | $33.75 | $5.78 |
| Average True Range (ATR) | 0.57 | 0.34 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 6.19 | 26.55 |
Artesian Resources Corp operates as a holding company based in the United States. Through its subsidiaries, it offers water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The Group distributes and sells water, including water for public and private fire protection, to residential, commercial, industrial, municipal, and utility customers. Additionally, it is involved in contract water and wastewater operations; offers wastewater services, and water, sewer, and internal Service Line Protection Plans. The Group operates its businesses mainly through one reportable segment, the Regulated Utility segment.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.